Ocrevus Effective in RRMS Patients With Poor Responses to Prior DMTs

Ocrevus Effective in RRMS Patients With Poor Responses to Prior DMTs

303092

Ocrevus Effective in RRMS Patients With Poor Responses to Prior DMTs

Ocrevus (ocrelizumab) safely and effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who responded poorly to other disease-modifying therapies (DMTs), final two-year data from the CHORDS Phase 3b clinical trial show. Notably, these benefits also were observed among patients who enrolled in the study based only on subclinical disease activity, highlighting the importance of switching to a new DMT, such as Ocrevus, when others have failed, even in patients without clinical…

You must be logged in to read/download the full post.